Eli Lilly and Company $LLY Stock Acquired by Guyasuta Investment Advisors Inc.

Key Points

• Guyasuta Investment Advisors increased its Eli Lilly stake by 359.1% in the third quarter, bringing its holdings to 11,817 shares valued at approximately $13.7 million. Institutional investors collectively own 82.53% of LLY.
• Several Eli Lilly executives sold shares under pre-arranged Rule 10b5-1 plans, with insiders selling 13,500 shares worth about $16.0 million over the past 90 days.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $1,313.43 target price. The company recently exceeded earnings and revenue expectations, though its premium valuation and elevated investor expectations remain risks.

Guyasuta Investment Advisors Inc. increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 359.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,817 shares of the company's stock after purchasing an additional 9,243 shares during the quarter. Guyasuta Investment Advisors Inc.'s holdings in Eli Lilly and Company were worth $13,673,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Whitener Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 9.3% during the 3rd quarter. Whitener Capital Management Inc. now owns 3,235 shares of the company's stock valued at $3,743,000 after purchasing an additional 275 shares during the last quarter. Walser Wealth Management Company A Ltd Liability Co lifted its stake in Eli Lilly and Company by 3.0% in the third quarter. Walser Wealth Management Company A Ltd Liability Co now owns 1,281 shares of the company's stock worth $1,482,000 after acquiring an additional 37 shares during the period. V Square Quantitative Management LLC increased its position in shares of Eli Lilly and Company by 9.0% during the third quarter. V Square Quantitative Management LLC now owns 18,530 shares of the company's stock valued at $21,441,000 after buying an additional 1,536 shares during the period. Fortitude Advisory Group L.L.C. raised its position in shares of Eli Lilly and Company by 5.4% in the 3rd quarter. Fortitude Advisory Group L.L.C. now owns 1,399 shares of the company's stock worth $1,618,000 after acquiring an additional 72 shares in the last quarter. Finally, First Merchants Corp lifted its position in Eli Lilly and Company by 5.3% during the third quarter. First Merchants Corp now owns 53,117 shares of the company's stock valued at $61,461,000 after buying an additional 2,689 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. HSBC upped their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th. Wall Street Zen downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an "overweight" rating in a research note on Thursday, October 8th. Royal Bank Of Canada restated an "outperform" rating and set a $1,500.00 target price on shares of Eli Lilly and Company in a research note on Monday, October 12th. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,313.43.

Eli Lilly and Company Stock Up 0.5%

NYSE LLY opened at $1,258.04 on Friday. The firm has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.22, a PEG ratio of 1.67 and a beta of 0.46. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65. The company has a fifty day moving average of $1,180.08 and a two-hundred day moving average of $1,107.98. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts predict that Eli Lilly and Company will post 33.56 earnings per share for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: European backing for Foundayo: The European Medicines Agency’s advisory committee issued a positive recommendation for Foundayo (orforglipron), Lilly’s once-daily oral GLP-1 treatment for obesity and type 2 diabetes. Final approval from the European Commission is still required, but the decision supports Lilly’s strategy to expand beyond injectable drugs and could broaden access to the rapidly growing weight-loss market. Eli Lilly’s GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
• Positive Sentiment: Additional obesity drugs could extend growth: Analysts and market commentators highlighted Foundayo, investigational retatrutide and other newer medicines as potential drivers of Lilly’s next growth phase, reducing dependence on Zepbound. Retatrutide remains in development, so its commercial contribution depends on clinical results and future regulatory approval. Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly’s Next Leg Higher
• Positive Sentiment: Pipeline diversification is improving: New Omvoh analyses showed meaningful one-year corticosteroid-free disease control in ulcerative colitis and Crohn’s disease, including patients who had failed prior biologics. Lilly also announced oncology research collaborations, adding potential long-term pipeline value beyond its GLP-1 franchise. New Omvoh Composite Outcomes Data
• Neutral Sentiment: Valuation remains a risk: Lilly’s exceptional obesity-driven growth and strong recent performance have pushed investor expectations high. Articles questioned whether future cash-flow growth is sufficient to justify the stock’s premium valuation, increasing the possibility of volatility if results or guidance disappoint. Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
• Negative Sentiment: Large shareholder sale adds a technical overhang: The Lilly Foundation is selling approximately 300,000 shares valued near $347 million. Reports indicate the transaction is not tied to concerns about Lilly’s business outlook, but a sizable sale can still raise short-term supply and sentiment concerns. Eli Lilly’s Biggest Shareholder Is Selling $347 Million of Stock

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.